Lawmakers seek the removal of Glavin

Share this article:
FDA associate commissioner for regulatory affairs Margaret O'K. Glavin should be removed from her post for sending a "retaliatory" all-hands memo to the agency's field employees shortly after congressional testimony by several dissident field managers gave the agency low grades for its food inspection performance, House Energy and Commerce leaders said in a letter to FDA commissioner Andrew von Eschenbach.

“(G)iven Ms. Glavin's blatant conduct, she should be removed from her position directing FDA field staff and replaced by someone who truly believes in reforming the way the FDA does business,” Oversight and Investigations Subcommittee chairman Bart Stupak (D-MI) was quoted in a news release as saying.

“At the same time, the commissioner needs to publicly repudiate and condemn her statements as contrary to the law and his policies at the FDA,” he continued.

Glavin's conduct could be a federal law violation, said full committee chairman John Dingell (D-MI). He added that her memo contradicted  previous testimony by von Eschenbach about not tolerating intimidation or retaliation of any kind.

Dingell is sponsoring a bill to prevent the FDA from proceeding with a plan by Glavin to close seven of the agency's 13 field laboratories and consolidate district offices, and to require any future closings to first gain congressional approval.

Share this article:

Email Newsletters

More in News

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...

Pfizer Q2 sales slip, but still beat expectations

Pfizer Q2 sales slip, but still beat expectations

Patent losses and lost co-promotion agreements put a dent in sales.

Lack of marketing partner delays Afrezza launch

Lack of marketing partner delays Afrezza launch

Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?